|1.||Kim, S J: 8 articles (09/2003 - 01/2000)|
|2.||Moses, Harold L: 7 articles (07/2010 - 05/2003)|
|3.||Lee, Chung: 6 articles (01/2010 - 01/2005)|
|4.||Zhang, Qiang: 6 articles (01/2010 - 01/2005)|
|5.||Guo, Yinglu: 4 articles (01/2010 - 02/2006)|
|6.||Serra, Rosa: 4 articles (07/2008 - 03/2005)|
|7.||Gorska, Agnieszka E: 4 articles (01/2008 - 05/2003)|
|8.||Chytil, Anna: 4 articles (01/2008 - 03/2005)|
|9.||Arteaga, Carlos L: 4 articles (05/2007 - 06/2002)|
|10.||Takenoshita, S: 4 articles (09/2006 - 07/2000)|
|1.||Radiation Injuries (Radiation Sickness)
|2.||Liver Cirrhosis (Hepatic Cirrhosis)
04/01/2006 - "Combination gene therapy of HGF and truncated type II TGF-beta receptor for rat liver cirrhosis after partial hepatectomy."
03/01/2009 - "Adenoviral delivery of dominant-negative transforming growth factor beta type II receptor up-regulates transcriptional repressor SKI-like oncogene, decreases matrix metalloproteinase 2 in hepatic stellate cell and prevents liver fibrosis in rats."
03/02/1999 - "We eliminated type beta transforming growth factor (TGF-beta) signaling by adenovirus-mediated local expression of a dominant-negative type II TGF-beta receptor (AdCATbeta-TR) in the liver of rats treated with dimethylnitrosamine, a model of persistent liver fibrosis. "
02/01/2010 - "Subsequent studies showed that the CC chemokine regulated on activation, normal T cell expressed, and presumably secreted was up-regulated in invasive tumors and was required for invasion in cells with repressed levels of the transforming growth factor-beta type II receptor. "
02/01/2009 - "Importantly, mouse oral tumors can be followed by in vivo imaging, show metastatic spreading to regional lymph nodes, and display activation of nuclear factor-kappaB and signal transducer and activator of transcription-3 pathways and decreased transforming growth factor-beta type II receptor expression, thus resembling human counterparts. "
03/15/2008 - "Cancer-associated transforming growth factor beta type II receptor gene mutant causes activation of bone morphogenic protein-Smads and invasive phenotype."
01/01/2005 - "No mutations in the type II TGF-beta receptor and Smad2 genes were observed in the tumors. "
03/01/2003 - "These mutations are similar to those of the 10-bp polyadenine tract within the TGF-beta type II receptor (TGFBR2), a well-characterized target of frameshift mutations in the same neoplasms. "
|4.||Squamous Cell Carcinoma (Epidermoid Carcinoma)
05/15/2006 - "Loss of transforming growth factor-beta type II receptor promotes metastatic head-and-neck squamous cell carcinoma."
10/01/2000 - "Mutation analysis of transforming growth factor beta type II receptor, Smad2, Smad3 and Smad4 in esophageal squamous cell carcinoma."
06/01/1999 - "Expression of transforming growth factor beta type II receptors in head and neck squamous cell carcinoma."
11/01/1997 - "Mutation and downregulation of the transforming growth factor beta type II receptor gene in primary squamous cell carcinomas of the head and neck."
09/15/1995 - "Missense mutations of the transforming growth factor beta type II receptor in human head and neck squamous carcinoma cells."
07/01/2005 - "Remote delivery and expression of soluble type II TGF-beta receptor in muscle prevents hepatic fibrosis in rats."
10/01/2003 - "These results indicate the superiority of a soluble type II TGF-beta receptor over a dominant-negative, non-soluble type II TGF-beta receptor in the context of blocking renal fibrosis in murine models."
10/01/2003 - "The biologic activity of the type II TGF-beta receptor was evaluated in vitro by its ability to inhibit cellular proliferation and in vivo in a unilateral ureter obstruction fibrosis model. "
10/26/1999 - "In vivo inhibition of rat stellate cell activation by soluble transforming growth factor beta type II receptor: a potential new therapy for hepatic fibrosis."
10/01/2009 - "Similar to tumors expressing dominant-negative TGF-beta type II receptor, histochemical studies revealed less fibrosis and increased angiogenesis in xenografted tumors expressing c-Ski compared to control tumors. "
|1.||Transforming Growth Factor beta (TGF-beta)
|2.||Transforming Growth Factors (Transforming Growth Factor)
|4.||Transforming Growth Factor beta1 (TGF beta 1)
|5.||Transforming Growth Factor beta3 (TGF beta 3)
|6.||TGF-beta type I receptor
|7.||Messenger RNA (mRNA)
|8.||Histone Deacetylases (Histone Deacetylase)
|9.||Carrier Proteins (Binding Protein)
|2.||Heterologous Transplantation (Xenotransplantation)